Idt Australia Limited · ASX:IDT
Idt Australia — Investor Presentation (April 2016)
19 slides from Idt Australia's investor presentation, Apr 14, 2016
Slide 1: Good Medicine
GOOD MEDICINE AjUO OSNn feuosJed JOS
Slide 2: Specialty Generic Drugs, Contract Manufacturing, Contract Clinical Services
For personal use only Specialty Generic Drugs Contract Manufacturing Contract Clinical Services
Slide 3: FDA Approval of Temozolomide
UPDATE 13APR16 FDA APPROVAL of TEMOZOLOMIDE For personal use only • IDT’s first proprietary generic product • First in a portfolio of 24 approved US specialty generic drugs • USD200m market opportunity • Distribution via Mayne Pharma • Fundamental and transformational change to the IDT strategy, bus
Slide 4: Investment Proposition
IDT AUSTRALIA LTD (ASX.IDT) INVESTMENT PROPOSITION For personal use only The Business: US FDA approved generic drug portfolio Aggregate Addressable Two in-house products, one FDA approved Market over US$750m Growing contract drug development revenues Growing contract drug manufacturing revenues Grow
Slide 5: A Platform for Rapid Growth
35 YEAR HISTORY A PLATFORM FOR RAPID GROWTH For personal use only IDT Service Business: IDT Specialty Generics: Provides revenues and capabilities Leverages facilities and multiplies margins Drug development services revenues Revenue Step Change via Proprietary IDT Generic Contract drug Drug Portfol
Slide 6: IDT Specialty Drug Portfolio: Approved US Generic Drugs
IDT SPECIALTY DRUG PORTFOLIO 24 APPROVED US GENERIC DRUGS For personal use only • Purchased Dec14, now being moved into IDT facility and first batches manufactured • Recently established partnership with ANI Pharma. (Nasdaq: ANIP) to commercialize first 18 • Addressable market of USD500m+ (Jun15 IMS
Slide 7: Portfolio Overview
IDT PORTFOLIO OVERVIEW For personal use only US Priority Product Sales Product Priority Manufacturer Distributor (USD, 2015) Aminophylline 3 ANI Carbidopa & 1 Wellspring ANI 65.2 Levodopa Ciprofloxacin 2 IDT ANI 44.5 Clarithromycin 2 Wellspring ANI 16.2 Dexamethasone 3 ANI Dextroamphetam 3 ANI ine D
Slide 8: Portfolio Overview
IDT PORTFOLIO OVERVIEW For personal use only Priority US Product Sales Product Priority Manufacturer Distributor (USD, 2015) Leucovorin 1 IDT ANI 1.4 Methoxsalen 2 IDT ANI Mexiletine 1 Wellspring ANI 11.6 Nefazodone 1 ANI 13.5 Nortriptyline 2 Wellspring ANI 24.6 Pindolol 1 Wellspring ANI 10.0 Prazos
Slide 9: Portfolio Snapshot as at 13Apr16
PORTFOLIO SNAPSHOT as at 13Apr16 For personal use only Marketing Temozolomide Development Manufactured Stability FDA Review Approval Doxazosin Development Manufactured Stability Leucovorin Development Manufactured Pindolol Development Thiotepa Development www.idtaus.com.au 9
Slide 10: World Class Manufacturing Facilities
GLOBALLYAPPROVED WORLD CLASS MANUFACTURING FACILITIES For personal use only SENSITIZING DRUGS ANTI–CANCER DRUGS HORMONES CARBOHYDRATE DRUGS HIGH CONTAINMENT TABS/CAPS HIGH CONTAINMENT TAB COATING www.idtaus.com.au 10
Slide 11: CMAX: Our Clinical Unit
CMAX OUR CLINICAL UNIT For personal use only CMAX clinical trials facility, Adelaide Australia’s oldest, largest, most experienced clinical trials unit 13,000 patient, well categorised database Brand new 50 bed clinical unit located opp Royal Adelaide Hospital Global client list with large amount of
Slide 12: Building an IDT Specialty Generic Portfolio
BUILDINGAN IDT SPECIALITY GENERIC PORTFOLIO For personal use only $$ MARGIN WITHIN VALUE CHAIN IDT REGISTRATION & SUPPLY DISTRIBUTOR IDT’s 2% API margin share WHOLESALER Generics margin up to 50 - 60% Example: PROJECT TETON: IDT currently the dominant supplier of active pharmaceutical ingredients fo
Slide 13: Good Medicine & Higher Returns for IDT
GOOD MEDICINE & HIGHER RETURNS FOR IDT For personal use only SELL MORE EXISTING PRODUCTS EXTRACT MORE PROFITS • High fixed costs = operational leverage. • Extract more profits from those products to • As a result, profits will rise faster than improve our share of the value chain. revenues past brea
Slide 14: Highlights of the Past Year
HIGHLIGHTS OF THE PAST YEAR For personal use only DEPLOYMENT OF GENERIC US DRUG PORTFOLIO ANI Pharma and Mayne Pharma appointed to distribute in US More manufacturing resources brought to bear on return to market BUILDING IN-HOUSE DRUG PORTFOLIO Filed first IDT ANDA for temozolomide November 13 (USD
Slide 15: Board & Management in Place to Deliver
BOARD & MANAGEMENT IN PLACE TO DELIVER For personal use only MANAGEMENT TEAM BOARD Dr Paul D R MacLeman (CEO & MD) Graeme Kaufman (Chairman) Deb Cailes (Market Access) Dr Paul D R MacLeman (MD) Jane Kelly (Clinical) Geoff Lord (Vice Chairman) Paul Loria (Reg & Quality) Dr Graeme Blackman (NED) Joann
Slide 16: Financially Positioned to Deliver
FINANCIALLY POSITIONED TO DELIVER For personal use only FINANCIALS (ASX: IDT) MARKET CAP $73.5m (13Apr16) FY2014 FY2015 1H FY2016 REVENUE $13.4m $15.7m $6.5m EARNINGS AFTER ($6.6m) ($3.0m) ($3.5m) TAX NET ASSETS $25.5m $39.2m $43.7m CAPITAL STRUCTURE CASH $2.40 $0.13 $4.90 DEBT* $0.1m $0.0m $0.0m SH
Slide 17: Target 2016 Milestones
TARGET 2016 MILESTONES For personal use only INCREASED ORGANIC SALES TOWARDS PROFITABILITY PROGRESS TEMOZOLOMIDE TO COMMERCIAL LAUNCH MOVEMENT OF AN ADDITIONAL INTERNAL PRODUCT TOWARDS MARKET PROGRESS WITH RE-COMMERCIALISATION OF US GENERIC PORTFOLIO ACROSS MULTIPLE SITES MOVE FROM SERVICE PROVIDER,
Slide 18: Contact Us
CONTACT US For personal use only Dr Paul D R MacLeman MANAGING DIRECTOR +61 (0) 3 9801 8888 info@idtaus.com.au www.idtaus.com.au www.idtaus.com.au 18
Slide 19: Questions and Answers
For personal use only QUESTIONS AND ANSWERS